Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01871727 · ClinicalTrials.gov registry record · Phase 3
A Trial of E7777 in Persistent and Recurrent Cutaneous T-Cell Lymphoma
A Phase 3 study, sponsored by Eisai.
- Completed
- Registry status
- Phase 3
- Development phase
- 112
- Enrollment target
NCT01871727 is a Phase 3 study that has completed, run by Eisai. The registered enrollment target is 112 participants.
The verdict
NCT01871727, a Phase 3 study, has completed, sponsored by Eisai.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 112 participants
- Enrollment target
Study Summary
The purpose of this trial is to assess the efficacy of E7777 in participants with recurrent or persistent Cutaneous T-Cell Lymphoma (CTCL) in Stage I - III participants as assessed by objective response rate (ORR). A lead-in dose-finding part was used to determine dose level 9 microgram per kilogram (mcg/kg) E7777 that is being used to test efficacy and safety.
Interventions
- DRUG E7777 9 mcg/kg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 112 participants |
| Start Date | 2013-05-30 |
| Est. Completion | 2021-12-14 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01871727
The ClinicalTrials.gov registry entry for NCT01871727 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 112 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eisai, which has 287 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which E7777 9 mcg/kg is the first listed.
NCT01871727 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01871727 about?
NCT01871727 is a clinical study titled "A Trial of E7777 in Persistent and Recurrent Cutaneous T-Cell Lymphoma". The purpose of this trial is to assess the efficacy of E7777 in participants with recurrent or persistent Cutaneous T-Cell Lymphoma (CTCL) in Stage I - III participants as assessed by objective response rate (ORR). A lead-in dose-finding part was used to determine dose level 9 microgram per kilogram...
What is the current status of trial NCT01871727?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 112 participants. The study started on 2013-05-30. Estimated completion is 2021-12-14.
What interventions are being tested in trial NCT01871727?
The interventions under investigation include: E7777 9 mcg/kg (DRUG).
Who is sponsoring clinical trial NCT01871727?
This trial is sponsored by Eisai, which has 287 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.